Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Compass Pathways appoints Wayne Riley to board of directors » 07:11
04/01/21
04/01
07:11
04/01/21
07:11
CMPS

Compass Pathways

$36.93 /

+1.54 (+4.35%)

Compass Pathways…

Compass Pathways announced that it has appointed Wayne Riley MD to its board of directors. Riley is President of the State University of New York Downstate Health Sciences University, Brooklyn, where he holds tenured professorships in internal medicine, and health policy and management. In addition, Riley is also chairman of the board of the New York Academy of Medicine, an elected member of the US National Academy of Medicine, a Commissioner of the US Medicare Payment Advisory Commission, and President of the Society of Medical Administrators. He is a President Emeritus of the American College of Physicians.

ShowHide Related Items >><<
CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

04/01/21 Roth Capital
Compass Pathways initiated with a Buy at Roth Capital
10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

  • 18
    Sep
CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

Initiation
Compass Pathways initiated with a Buy at Roth Capital » 06:58
04/01/21
04/01
06:58
04/01/21
06:58
CMPS

Compass Pathways

$36.93 /

+1.54 (+4.35%)

Roth Capital analyst…

Roth Capital analyst Elemer Piros initiated coverage of Compass Pathways with a Buy rating and $88 price target. Compass is at the "forefront" of bringing the first psychedelic drug to market for treatment-resistant depression, Piros tells investors in a research note. He believes the company is "leading the way" to properly evaluate gaining eventual approval of psychedelic drugs for mental illness. Compass has obtained Breakthrough Therapy designation for psilocybin in treatment-resistant depression and plans to complete a 216-patient Phase 2b trial by the end of 2021, Piros notes. With a "relatively small," 5% penetration, the company could achieve $8B in sales in the U.S. and Europe combined, says the analyst.

ShowHide Related Items >><<
CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

  • 18
    Sep
CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

CMPS Compass Pathways
$36.93 /

+1.54 (+4.35%)

Hot Stocks
Compass announces USPTO grants patents for psilocybin in depression treatment » 08:17
03/23/21
03/23
08:17
03/23/21
08:17
CMPS

Compass Pathways

$38.27 /

-1.24 (-3.14%)

Compass Pathways…

Compass Pathways announced that it has been granted two new patents by the US Patent and Trademark Office . These patents cover oral formulations of COMPASS's synthetic psilocybin in the treatment of major depressive disorder, which includes treatment-resistant depression. US Patent No 10,954,259 was granted on 23 March 2021, with claims to COMPASS's high-purity crystalline psilocybin, pharmaceutical formulations containing crystalline psilocybin and methods of treating MDD with the crystalline psilocybin. US Patent No 10,947,257 was granted on 16 March 2021, with claims to oral dosage forms of crystalline psilocybin and methods of treating MDD with the oral dosage forms. "These patents are a critical milestone in our efforts to establish a new evidence-based option to help patients with depression in the US," said George Goldsmith, CEO and Co-founder of COMPASS Pathways. "Through these grants, the USPTO has recognised our innovations. These decisions enable us to continue to do the highest quality clinical research and bring potentially life-changing care to patients who might benefit from this therapy." COMPASS's first US patent, No 10,519,175, was granted in December 2019 and covers the use of formulations of COMPASS's high-purity crystalline psilocybin in psilocybin therapy for patients with TRD.

ShowHide Related Items >><<
CMPS Compass Pathways
$38.27 /

-1.24 (-3.14%)

CMPS Compass Pathways
$38.27 /

-1.24 (-3.14%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
CMPS Compass Pathways
$38.27 /

-1.24 (-3.14%)

  • 18
    Sep
CMPS Compass Pathways
$38.27 /

-1.24 (-3.14%)

CMPS Compass Pathways
$38.27 /

-1.24 (-3.14%)

Over a month ago
Earnings
Compass Pathways reports Q4 EPS (52c), consensus ($1.05) » 07:15
03/09/21
03/09
07:15
03/09/21
07:15
CMPS

Compass Pathways

$39.61 /

-1.3 (-3.18%)

George Goldsmith,…

George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, "Mental health is an urgent crisis and this has only been exacerbated by the COVID-19 pandemic. At COMPASS we remain committed to transforming mental health care and helping patients who are suffering and aren't helped by existing treatments. Our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression is actively recruiting and we plan to report data from this trial at the end of the year. We are also continuing preclinical research into new indications, new compounds and new technologies, working with partners through our Centre of Excellence, our Discovery Center, and a number of investigator-initiated studies, as well as developing a strong team."

ShowHide Related Items >><<
CMPS Compass Pathways
$39.61 /

-1.3 (-3.18%)

CMPS Compass Pathways
$39.61 /

-1.3 (-3.18%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
CMPS Compass Pathways
$39.61 /

-1.3 (-3.18%)

  • 18
    Sep
CMPS Compass Pathways
$39.61 /

-1.3 (-3.18%)

CMPS Compass Pathways
$39.61 /

-1.3 (-3.18%)

Hot Stocks
Compass Pathways expands Discovery Center through lab collaborations » 07:27
02/09/21
02/09
07:27
02/09/21
07:27
CMPS

Compass Pathways

$45.70 /

+0.69 (+1.53%)

COMPASS Pathways…

COMPASS Pathways announced that it has expanded its Discovery Center, through collaborations with world-leading laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin. Adam Halberstadt PhD, Associate Professor, Psychiatry, UC San Diego, and John D McCorvy PhD, Assistant Professor, Department of Cell Biology, Neurobiology and Anatomy, MCW, and their teams, will join Jason Wallach PhD, Assistant Professor of Pharmaceutical Sciences, University of the Sciences at the Discovery Center, a group of researchers working together, virtually. The COMPASS Discovery Center was established in August 2020 through a sponsored research agreement between COMPASS and University of the Sciences. It is led by Jason Wallach's laboratory at University of the Sciences and is now expanding its research network across the US, with Adam Halberstadt in San Diego, and John McCorvy in Wisconsin. The scientists intend to develop new, optimised psychedelic compounds to address unmet medical need. COMPASS will be the exclusive licensee for all new compounds generated.

ShowHide Related Items >><<
CMPS Compass Pathways
$45.70 /

+0.69 (+1.53%)

CMPS Compass Pathways
$45.70 /

+0.69 (+1.53%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
CMPS Compass Pathways
$45.70 /

+0.69 (+1.53%)

  • 18
    Sep
CMPS Compass Pathways
$45.70 /

+0.69 (+1.53%)

CMPS Compass Pathways
$45.70 /

+0.69 (+1.53%)

Hot Stocks
Compass announces publication on therapist training program for psilocybin » 07:32
02/03/21
02/03
07:32
02/03/21
07:32
CMPS

Compass Pathways

$42.48 /

+0.03 (+0.07%)

COMPASS Pathways has…

COMPASS Pathways has shared details of its comprehensive and rigorous therapist training programme for psilocybin therapy, in a paper jointly written with a group of academic researchers, and published in Frontiers in Psychiatry today. The programme sets out a formal and scalable methodology for psychological support in psilocybin therapy. It is currently being used to train therapists taking part in COMPASS's phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, as approved by the US Food and Drug Administration, as part of COMPASS's Investigational New Drug application. In psilocybin therapy, patients are given a dose of psilocybin, a psychedelic substance, in conjunction with psychological support from specially trained therapists. COMPASS developed the therapist training programme alongside leading experts in mental health and psychedelic research, including William A Richards, Elizabeth Nielson, Riikka Ajantaival, Peter Gasser, Sara J Tai, Brian D Richards, and Frederick Reinholdt. The programme uses a new and manualised approach drawing from evidence-based psychotherapeutic approaches, and currently comprises four components: an online learning platform; in-person training; applied clinical training; and ongoing individual mentoring and professional development. In previous psilocybin studies, the approach to psychological support often varied between research sites, making it difficult to replicate and distinguish the specific effects of psilocybin from concurrent therapeutic interventions. Equally, training in the provision of psychological support had not been defined and evaluated. This manualised training programme begins to address this gap and is the start of a process that will continue to be refined and adapted as clinical trials of psilocybin therapy progress. Therapists who participated in the training reported that the combination of didactic and experiential learning helped them to build conceptual understanding and develop their skills in the therapeutic approach. From the programme feedback, the clinical training and engagement in participant care, under the guidance of experienced therapists, were considered to be the most beneficial and challenging aspects of the training.

ShowHide Related Items >><<
CMPS Compass Pathways
$42.48 /

+0.03 (+0.07%)

CMPS Compass Pathways
$42.48 /

+0.03 (+0.07%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
CMPS Compass Pathways
$42.48 /

+0.03 (+0.07%)

  • 18
    Sep
CMPS Compass Pathways
$42.48 /

+0.03 (+0.07%)

CMPS Compass Pathways
$42.48 /

+0.03 (+0.07%)

Over a quarter ago
Hot Stocks
Compass Pathways establishes Center of Excellence with Sheppard Pratt » 07:02
01/08/21
01/08
07:02
01/08/21
07:02
CMPS

Compass Pathways

$46.45 /

-0.22 (-0.47%)

COMPASS Pathway is…

COMPASS Pathway is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States. The company said, "The Centre of Excellence will model the "clinic of the future", showcasing the best thinking in science, therapy, technology, and design. Working as a research facility and innovation lab, it will generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience. The first wave of research will focus on COMPASS's investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists...The Centre of Excellence will be led by Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, a distinguished fellow of the American Psychiatric Association and a fellow of the American College of Psychiatrists. The Centre of Excellence will be built on the Sheppard Pratt Towson campus and will include at least four state-of-the-art psychedelic therapy rooms, as well as facilities for research and training. In addition to a capital investment to support the design and building work, COMPASS will fund research studies into psilocybin therapy and other therapies, led by Dr Aaronson. "

ShowHide Related Items >><<
CMPS Compass Pathways
$46.45 /

-0.22 (-0.47%)

CMPS Compass Pathways
$46.45 /

-0.22 (-0.47%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
CMPS Compass Pathways
$46.45 /

-0.22 (-0.47%)

  • 18
    Sep
CMPS Compass Pathways
$46.45 /

-0.22 (-0.47%)

CMPS Compass Pathways
$46.45 /

-0.22 (-0.47%)

Conference/Events
Evercore ISI to hold a virtual conference » 04:55
12/03/20
12/03
04:55
12/03/20
04:55
CMPS

Compass Pathways

$47.94 /

+3.21 (+7.18%)

, INSM

Insmed

$39.74 /

+0.71 (+1.82%)

, ALXN

Alexion

$122.70 /

+0.55 (+0.45%)

, ENTA

Enanta

$42.11 /

+1.06 (+2.58%)

, NKTX

Nkarta

$33.99 /

-0.02 (-0.06%)

, HRC

Hill-Rom

$96.12 /

-0.16 (-0.17%)

, DRNA

Dicerna

$24.45 /

-0.31 (-1.25%)

, ZBH

Zimmer Biomet

$147.88 /

+1.77 (+1.21%)

, INCY

Incyte

$82.30 /

-3.14 (-3.68%)

, MTEM

Molecular Templates

$8.68 /

-0.16 (-1.81%)

, KOD

Kodiak Sciences

$130.73 /

+0.35 (+0.27%)

, ICLR

Icon

$199.11 /

+1.67 (+0.85%)

, MCRB

Seres Therapeutics

$25.14 /

-1.2 (-4.56%)

, NVST

Envista

$31.12 /

+1.06 (+3.53%)

, EXEL

Exelixis

$19.32 /

+0.17 (+0.89%)

, FATE

Fate Therapeutics

$60.50 /

+0.35 (+0.58%)

, FOLD

Amicus

$23.25 /

+0.58 (+2.56%)

, COGT

Cogent Biosciences

$12.15 /

+1.63 (+15.49%)

, BHC

Bausch Health

$19.06 /

+0.42 (+2.25%)

, TBIO

Translate Bio

$22.49 /

+0.25 (+1.12%)

, STRO

Sutro Biopharma

$16.37 /

-0.4 (-2.39%)

, PRAX

Praxis Precision Medicines

$43.98 /

+1.51 (+3.56%)

3rd Annual HealthCONx…

3rd Annual HealthCONx Virtual Conference will be held on December 1-3.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$147.88 /

+1.77 (+1.21%)

TBIO Translate Bio
$22.49 /

+0.25 (+1.12%)

STRO Sutro Biopharma
$16.37 /

-0.4 (-2.39%)

PRAX Praxis Precision Medicines
$43.98 /

+1.51 (+3.56%)

NVST Envista
$31.12 /

+1.06 (+3.53%)

NKTX Nkarta
$33.99 /

-0.02 (-0.06%)

MTEM Molecular Templates
$8.68 /

-0.16 (-1.81%)

MCRB Seres Therapeutics
$25.14 /

-1.2 (-4.56%)

KOD Kodiak Sciences
$130.73 /

+0.35 (+0.27%)

INSM Insmed
$39.74 /

+0.71 (+1.82%)

INCY Incyte
$82.30 /

-3.14 (-3.68%)

ICLR Icon
$199.11 /

+1.67 (+0.85%)

HRC Hill-Rom
$96.12 /

-0.16 (-0.17%)

FOLD Amicus
$23.25 /

+0.58 (+2.56%)

FATE Fate Therapeutics
$60.50 /

+0.35 (+0.58%)

EXEL Exelixis
$19.32 /

+0.17 (+0.89%)

ENTA Enanta
$42.11 /

+1.06 (+2.58%)

DRNA Dicerna
$24.45 /

-0.31 (-1.25%)

COGT Cogent Biosciences
$12.15 /

+1.63 (+15.49%)

CMPS Compass Pathways
$47.94 /

+3.21 (+7.18%)

BHC Bausch Health
$19.06 /

+0.42 (+2.25%)

ALXN Alexion
$122.70 /

+0.55 (+0.45%)

CMPS Compass Pathways
$47.94 /

+3.21 (+7.18%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
INSM Insmed
$39.74 /

+0.71 (+1.82%)

11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
10/12/20 Stifel
Insmed resumed with a Buy at Stifel
04/23/20 JMP Securities
JMP reiterates $50 target on Insmed on planned COVID-19 trial
ALXN Alexion
$122.70 /

+0.55 (+0.45%)

11/20/20
Fly Intel: Top five analyst initiations
11/20/20 Bernstein
Alexion initiated with a Market Perform at Bernstein
11/19/20 Bernstein
Alexion initiated with a Market Perform at Bernstein
11/05/20 Citi
Alexion price target raised to $157 from $145 at Citi
ENTA Enanta
$42.11 /

+1.06 (+2.58%)

11/24/20 RBC Capital
Enanta price target lowered to $45 from $52 at RBC Capital
11/24/20 Evercore ISI
Evercore cautious on Enanta into 2021, starts with Underperform
11/23/20 Evercore ISI
Enanta initiated with an Underperform at Evercore ISI
10/26/20 Roth Capital
Enanta price target raised to $107 from $104 at Roth Capital
NKTX Nkarta
$33.99 /

-0.02 (-0.06%)

10/06/20 Mizuho
Nkarta CFO departure should not impact shares, says Mizuho
08/04/20 Mizuho
Mizuho starts Nkarta with Buy rating, $34 price target
08/04/20 Evercore ISI
Nkarta initiated with an Outperform at Evercore ISI
08/04/20 Stifel
Nkarta initiated with a Buy at Stifel
HRC Hill-Rom
$96.12 /

-0.16 (-0.17%)

11/04/20
Fly Intel: Top five analyst downgrades
11/04/20
Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
11/04/20 Needham
Hill-Rom downgraded to Hold from Buy at Needham
10/01/20 KeyBanc
Hill-Rom price target lowered to $115 from $138 at KeyBanc
DRNA Dicerna
$24.45 /

-0.31 (-1.25%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
ZBH Zimmer Biomet
$147.88 /

+1.77 (+1.21%)

11/09/20 SVB Leerink
Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
11/09/20 Credit Suisse
Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
11/09/20 Baird
Zimmer Biomet valuation discount to peers hard to justify, says at Baird
11/09/20 Oppenheimer
Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
INCY Incyte
$82.30 /

-3.14 (-3.68%)

11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
MTEM Molecular Templates
$8.68 /

-0.16 (-1.81%)

09/08/20 Jefferies
Molecular Templates initiated with a Buy at Jefferies
08/07/20
Molecular Templates files $300M mixed securities shelf
05/12/20 Oppenheimer
Molecular Templates price target raised to $22 from $16 at Oppenheimer
03/25/20
Fly Intel: Top five analyst initiations
KOD Kodiak Sciences
$130.73 /

+0.35 (+0.27%)

11/30/20
Fly Intel: Top five analyst downgrades
11/30/20 JPMorgan
Kodiak Sciences downgraded to Neutral on valuation at JPMorgan
11/30/20 JPMorgan
Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan
11/16/20 Morgan Stanley
Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts
ICLR Icon
$199.11 /

+1.67 (+0.85%)

10/23/20 Deutsche Bank
Icon price target raised to $179 from $170 at Deutsche Bank
10/23/20 Mizuho
Icon price target raised to $217 from $195 at Mizuho
10/22/20 Credit Suisse
Icon price target raised to $235 from $230 at Credit Suisse
07/27/20 Truist
SunTrust raises price targets on select late-stage CROs
MCRB Seres Therapeutics
$25.14 /

-1.2 (-4.56%)

11/09/20 Oppenheimer
Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
11/09/20 Piper Sandler
Seres Therapeutics price target raised to $49 from $40 at Piper Sandler
10/27/20 Oppenheimer
Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
10/26/20 Oppenheimer
Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
NVST Envista
$31.12 /

+1.06 (+3.53%)

10/30/20 JPMorgan
Envista price target raised to $30 from $28 at JPMorgan
10/30/20 Piper Sandler
Envista price target raised to $28 from $22 at Piper Sandler
07/31/20 Piper Sandler
Envista price target raised to $22 from $20 at Piper Sandler
06/16/20
Fly Intel: Top five analyst initiations
EXEL Exelixis
$19.32 /

+0.17 (+0.89%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
FATE Fate Therapeutics
$60.50 /

+0.35 (+0.58%)

12/02/20 Barclays
Fate Therapeutics price target raised to $70 from $60 at Barclays
11/24/20 Truist
Fate Therapeutics price target raised to $65 from $40 at Truist
11/09/20 Citi
Fate Therapeutics price target raised to $63 from $40 at Citi
11/08/20 Oppenheimer
Fate Therapeutics price target raised to $60 from $40 at Oppenheimer
FOLD Amicus
$23.25 /

+0.58 (+2.56%)

11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Amicus initiated with a Hold at Berenberg
11/06/20 Baird
Amicus price target raised to $25 from $20 at Baird
08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
COGT Cogent Biosciences
$12.15 /

+1.63 (+15.49%)

11/10/20 Wedbush
Cogent Biosciences price target raised to $24 from $6 at Wedbush
10/14/20 Ladenburg
Ladenburg starts Cogent Biosciences with Buy, $4 price target
10/14/20 Ladenburg
Cogent Biosciences initiated with a Buy at Ladenburg
BHC Bausch Health
$19.06 /

+0.42 (+2.25%)

11/05/20 Piper Sandler
Bausch Health price target lowered to $25 from $26 at Piper Sandler
10/26/20 Barclays
Bausch Health price target raised to $29 from $28 at Barclays
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 BofA
Bausch Health upgraded to Neutral from Underperform at BofA
TBIO Translate Bio
$22.49 /

+0.25 (+1.12%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
STRO Sutro Biopharma
$16.37 /

-0.4 (-2.39%)

12/02/20 Stifel
Sutro Biopharma initiated with a Buy at Stifel
11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
PRAX Praxis Precision Medicines
$43.98 /

+1.51 (+3.56%)

11/17/20 Piper Sandler
Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
11/11/20
Fly Intel: Top five analyst initiations
11/11/20 Wedbush
Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
11/11/20 Wedbush
Praxis Precision Medicines initiated with an Outperform at Wedbush
ZBH Zimmer Biomet
$147.88 /

+1.77 (+1.21%)

STRO Sutro Biopharma
$16.37 /

-0.4 (-2.39%)

NVST Envista
$31.12 /

+1.06 (+3.53%)

MTEM Molecular Templates
$8.68 /

-0.16 (-1.81%)

MCRB Seres Therapeutics
$25.14 /

-1.2 (-4.56%)

KOD Kodiak Sciences
$130.73 /

+0.35 (+0.27%)

INSM Insmed
$39.74 /

+0.71 (+1.82%)

INCY Incyte
$82.30 /

-3.14 (-3.68%)

ICLR Icon
$199.11 /

+1.67 (+0.85%)

HRC Hill-Rom
$96.12 /

-0.16 (-0.17%)

FOLD Amicus
$23.25 /

+0.58 (+2.56%)

FATE Fate Therapeutics
$60.50 /

+0.35 (+0.58%)

EXEL Exelixis
$19.32 /

+0.17 (+0.89%)

ENTA Enanta
$42.11 /

+1.06 (+2.58%)

DRNA Dicerna
$24.45 /

-0.31 (-1.25%)

COGT Cogent Biosciences
$12.15 /

+1.63 (+15.49%)

CMPS Compass Pathways
$47.94 /

+3.21 (+7.18%)

BHC Bausch Health
$19.06 /

+0.42 (+2.25%)

ALXN Alexion
$122.70 /

+0.55 (+0.45%)

  • 02
    Dec
  • 18
    Nov
  • 16
    Oct
  • 18
    Sep
  • 13
    Aug
  • 10
    Jul
  • 26
    Jun
  • 09
    Jun
  • 12
    May
  • 05
    May
  • 04
    Dec
TBIO Translate Bio
$22.49 /

+0.25 (+1.12%)

FOLD Amicus
$23.25 /

+0.58 (+2.56%)

CMPS Compass Pathways
$47.94 /

+3.21 (+7.18%)

ALXN Alexion
$122.70 /

+0.55 (+0.45%)

TBIO Translate Bio
$22.49 /

+0.25 (+1.12%)

STRO Sutro Biopharma
$16.37 /

-0.4 (-2.39%)

PRAX Praxis Precision Medicines
$43.98 /

+1.51 (+3.56%)

NVST Envista
$31.12 /

+1.06 (+3.53%)

NKTX Nkarta
$33.99 /

-0.02 (-0.06%)

MTEM Molecular Templates
$8.68 /

-0.16 (-1.81%)

MCRB Seres Therapeutics
$25.14 /

-1.2 (-4.56%)

KOD Kodiak Sciences
$130.73 /

+0.35 (+0.27%)

FOLD Amicus
$23.25 /

+0.58 (+2.56%)

ENTA Enanta
$42.11 /

+1.06 (+2.58%)

COGT Cogent Biosciences
$12.15 /

+1.63 (+15.49%)

BHC Bausch Health
$19.06 /

+0.42 (+2.25%)

ALXN Alexion
$122.70 /

+0.55 (+0.45%)

ALXN Alexion
$122.70 /

+0.55 (+0.45%)

STRO Sutro Biopharma
$16.37 /

-0.4 (-2.39%)

MCRB Seres Therapeutics
$25.14 /

-1.2 (-4.56%)

INCY Incyte
$82.30 /

-3.14 (-3.68%)

CMPS Compass Pathways
$47.94 /

+3.21 (+7.18%)

BHC Bausch Health
$19.06 /

+0.42 (+2.25%)

ALXN Alexion
$122.70 /

+0.55 (+0.45%)

Conference/Events
Evercore ISI to hold a virtual conference » 04:55
12/02/20
12/02
04:55
12/02/20
04:55
CMPS

Compass Pathways

$44.73 /

-4.78 (-9.65%)

, INSM

Insmed

$39.05 /

+0.03 (+0.08%)

, ALXN

Alexion

$122.16 /

+0.19 (+0.16%)

, ENTA

Enanta

$41.12 /

+0.01 (+0.02%)

, NKTX

Nkarta

$34.02 /

+1.09 (+3.31%)

, HRC

Hill-Rom

$96.26 /

+1.325 (+1.40%)

, DRNA

Dicerna

$24.76 /

-0.53 (-2.10%)

, ZBH

Zimmer Biomet

$146.00 /

-3.175 (-2.13%)

, INCY

Incyte

$85.42 /

+0.9 (+1.06%)

, MTEM

Molecular Templates

$8.85 /

-0.1 (-1.12%)

, KOD

Kodiak Sciences

$130.37 /

-6.31 (-4.62%)

, ICLR

Icon

$197.44 /

+2.59 (+1.33%)

, MCRB

Seres Therapeutics

$26.34 /

-1.2 (-4.36%)

, NVST

Envista

$30.06 /

+0.31 (+1.04%)

, EXEL

Exelixis

$19.15 /

+0.02 (+0.10%)

, FATE

Fate Therapeutics

$60.15 /

+1.68 (+2.87%)

, FOLD

Amicus

$22.66 /

-0.28 (-1.22%)

, COGT

Cogent Biosciences

$10.52 /

+0.56 (+5.62%)

, BHC

Bausch Health

$18.65 /

+0.065 (+0.35%)

, TBIO

Translate Bio

$22.25 /

+0.03 (+0.14%)

, STRO

Sutro Biopharma

$16.76 /

-0.32 (-1.87%)

, PRAX

Praxis Precision Medicines

$42.43 /

+1.49 (+3.64%)

3rd Annual HealthCONx…

3rd Annual HealthCONx Virtual Conference will be held on December 1-3.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$146.00 /

-3.175 (-2.13%)

TBIO Translate Bio
$22.25 /

+0.03 (+0.14%)

STRO Sutro Biopharma
$16.76 /

-0.32 (-1.87%)

PRAX Praxis Precision Medicines
$42.43 /

+1.49 (+3.64%)

NVST Envista
$30.06 /

+0.31 (+1.04%)

NKTX Nkarta
$34.02 /

+1.09 (+3.31%)

MTEM Molecular Templates
$8.85 /

-0.1 (-1.12%)

MCRB Seres Therapeutics
$26.34 /

-1.2 (-4.36%)

KOD Kodiak Sciences
$130.37 /

-6.31 (-4.62%)

INSM Insmed
$39.05 /

+0.03 (+0.08%)

INCY Incyte
$85.42 /

+0.9 (+1.06%)

ICLR Icon
$197.44 /

+2.59 (+1.33%)

HRC Hill-Rom
$96.26 /

+1.325 (+1.40%)

FOLD Amicus
$22.66 /

-0.28 (-1.22%)

FATE Fate Therapeutics
$60.15 /

+1.68 (+2.87%)

EXEL Exelixis
$19.15 /

+0.02 (+0.10%)

ENTA Enanta
$41.12 /

+0.01 (+0.02%)

DRNA Dicerna
$24.76 /

-0.53 (-2.10%)

COGT Cogent Biosciences
$10.52 /

+0.56 (+5.62%)

CMPS Compass Pathways
$44.73 /

-4.78 (-9.65%)

BHC Bausch Health
$18.65 /

+0.065 (+0.35%)

ALXN Alexion
$122.16 /

+0.19 (+0.16%)

CMPS Compass Pathways
$44.73 /

-4.78 (-9.65%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
INSM Insmed
$39.05 /

+0.03 (+0.08%)

11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
10/12/20 Stifel
Insmed resumed with a Buy at Stifel
04/23/20 JMP Securities
JMP reiterates $50 target on Insmed on planned COVID-19 trial
ALXN Alexion
$122.16 /

+0.19 (+0.16%)

11/20/20
Fly Intel: Top five analyst initiations
11/20/20 Bernstein
Alexion initiated with a Market Perform at Bernstein
11/19/20 Bernstein
Alexion initiated with a Market Perform at Bernstein
11/05/20 Citi
Alexion price target raised to $157 from $145 at Citi
ENTA Enanta
$41.12 /

+0.01 (+0.02%)

11/24/20 RBC Capital
Enanta price target lowered to $45 from $52 at RBC Capital
11/24/20 Evercore ISI
Evercore cautious on Enanta into 2021, starts with Underperform
11/23/20 Evercore ISI
Enanta initiated with an Underperform at Evercore ISI
10/26/20 Roth Capital
Enanta price target raised to $107 from $104 at Roth Capital
NKTX Nkarta
$34.02 /

+1.09 (+3.31%)

10/06/20 Mizuho
Nkarta CFO departure should not impact shares, says Mizuho
08/04/20 Mizuho
Mizuho starts Nkarta with Buy rating, $34 price target
08/04/20 Evercore ISI
Nkarta initiated with an Outperform at Evercore ISI
08/04/20 Stifel
Nkarta initiated with a Buy at Stifel
HRC Hill-Rom
$96.26 /

+1.325 (+1.40%)

11/04/20
Fly Intel: Top five analyst downgrades
11/04/20
Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
11/04/20 Needham
Hill-Rom downgraded to Hold from Buy at Needham
10/01/20 KeyBanc
Hill-Rom price target lowered to $115 from $138 at KeyBanc
DRNA Dicerna
$24.76 /

-0.53 (-2.10%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
ZBH Zimmer Biomet
$146.00 /

-3.175 (-2.13%)

11/09/20 SVB Leerink
Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
11/09/20 Credit Suisse
Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
11/09/20 Baird
Zimmer Biomet valuation discount to peers hard to justify, says at Baird
11/09/20 Oppenheimer
Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
INCY Incyte
$85.42 /

+0.9 (+1.06%)

11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
MTEM Molecular Templates
$8.85 /

-0.1 (-1.12%)

09/08/20 Jefferies
Molecular Templates initiated with a Buy at Jefferies
08/07/20
Molecular Templates files $300M mixed securities shelf
05/12/20 Oppenheimer
Molecular Templates price target raised to $22 from $16 at Oppenheimer
03/25/20
Fly Intel: Top five analyst initiations
KOD Kodiak Sciences
$130.37 /

-6.31 (-4.62%)

11/30/20
Fly Intel: Top five analyst downgrades
11/30/20 JPMorgan
Kodiak Sciences downgraded to Neutral on valuation at JPMorgan
11/30/20 JPMorgan
Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan
11/16/20 Morgan Stanley
Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts
ICLR Icon
$197.44 /

+2.59 (+1.33%)

10/23/20 Deutsche Bank
Icon price target raised to $179 from $170 at Deutsche Bank
10/23/20 Mizuho
Icon price target raised to $217 from $195 at Mizuho
10/22/20 Credit Suisse
Icon price target raised to $235 from $230 at Credit Suisse
07/27/20 Truist
SunTrust raises price targets on select late-stage CROs
MCRB Seres Therapeutics
$26.34 /

-1.2 (-4.36%)

11/09/20 Oppenheimer
Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
11/09/20 Piper Sandler
Seres Therapeutics price target raised to $49 from $40 at Piper Sandler
10/27/20 Oppenheimer
Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
10/26/20 Oppenheimer
Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
NVST Envista
$30.06 /

+0.31 (+1.04%)

10/30/20 JPMorgan
Envista price target raised to $30 from $28 at JPMorgan
10/30/20 Piper Sandler
Envista price target raised to $28 from $22 at Piper Sandler
07/31/20 Piper Sandler
Envista price target raised to $22 from $20 at Piper Sandler
06/16/20
Fly Intel: Top five analyst initiations
EXEL Exelixis
$19.15 /

+0.02 (+0.10%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
FATE Fate Therapeutics
$60.15 /

+1.68 (+2.87%)

11/24/20 Truist
Fate Therapeutics price target raised to $65 from $40 at Truist
11/09/20 Citi
Fate Therapeutics price target raised to $63 from $40 at Citi
11/08/20 Oppenheimer
Fate Therapeutics price target raised to $60 from $40 at Oppenheimer
11/06/20 Piper Sandler
Fate Therapeutics price target raised to $71 from $59 at Piper Sandler
FOLD Amicus
$22.66 /

-0.28 (-1.22%)

11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Amicus initiated with a Hold at Berenberg
11/06/20 Baird
Amicus price target raised to $25 from $20 at Baird
08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
COGT Cogent Biosciences
$10.52 /

+0.56 (+5.62%)

11/10/20 Wedbush
Cogent Biosciences price target raised to $24 from $6 at Wedbush
10/14/20 Ladenburg
Ladenburg starts Cogent Biosciences with Buy, $4 price target
10/14/20 Ladenburg
Cogent Biosciences initiated with a Buy at Ladenburg
BHC Bausch Health
$18.65 /

+0.065 (+0.35%)

11/05/20 Piper Sandler
Bausch Health price target lowered to $25 from $26 at Piper Sandler
10/26/20 Barclays
Bausch Health price target raised to $29 from $28 at Barclays
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 BofA
Bausch Health upgraded to Neutral from Underperform at BofA
TBIO Translate Bio
$22.25 /

+0.03 (+0.14%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
STRO Sutro Biopharma
$16.76 /

-0.32 (-1.87%)

11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
PRAX Praxis Precision Medicines
$42.43 /

+1.49 (+3.64%)

11/17/20 Piper Sandler
Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
11/11/20
Fly Intel: Top five analyst initiations
11/11/20 Wedbush
Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
11/11/20 Wedbush
Praxis Precision Medicines initiated with an Outperform at Wedbush
ZBH Zimmer Biomet
$146.00 /

-3.175 (-2.13%)

STRO Sutro Biopharma
$16.76 /

-0.32 (-1.87%)

NVST Envista
$30.06 /

+0.31 (+1.04%)

MTEM Molecular Templates
$8.85 /

-0.1 (-1.12%)

MCRB Seres Therapeutics
$26.34 /

-1.2 (-4.36%)

KOD Kodiak Sciences
$130.37 /

-6.31 (-4.62%)

INSM Insmed
$39.05 /

+0.03 (+0.08%)

INCY Incyte
$85.42 /

+0.9 (+1.06%)

ICLR Icon
$197.44 /

+2.59 (+1.33%)

HRC Hill-Rom
$96.26 /

+1.325 (+1.40%)

FOLD Amicus
$22.66 /

-0.28 (-1.22%)

FATE Fate Therapeutics
$60.15 /

+1.68 (+2.87%)

EXEL Exelixis
$19.15 /

+0.02 (+0.10%)

ENTA Enanta
$41.12 /

+0.01 (+0.02%)

DRNA Dicerna
$24.76 /

-0.53 (-2.10%)

COGT Cogent Biosciences
$10.52 /

+0.56 (+5.62%)

CMPS Compass Pathways
$44.73 /

-4.78 (-9.65%)

BHC Bausch Health
$18.65 /

+0.065 (+0.35%)

ALXN Alexion
$122.16 /

+0.19 (+0.16%)

  • 02
    Dec
  • 18
    Nov
  • 16
    Oct
  • 18
    Sep
  • 13
    Aug
  • 10
    Jul
  • 26
    Jun
  • 09
    Jun
  • 12
    May
  • 05
    May
  • 04
    Dec
TBIO Translate Bio
$22.25 /

+0.03 (+0.14%)

FOLD Amicus
$22.66 /

-0.28 (-1.22%)

CMPS Compass Pathways
$44.73 /

-4.78 (-9.65%)

ALXN Alexion
$122.16 /

+0.19 (+0.16%)

TBIO Translate Bio
$22.25 /

+0.03 (+0.14%)

STRO Sutro Biopharma
$16.76 /

-0.32 (-1.87%)

PRAX Praxis Precision Medicines
$42.43 /

+1.49 (+3.64%)

NVST Envista
$30.06 /

+0.31 (+1.04%)

NKTX Nkarta
$34.02 /

+1.09 (+3.31%)

MTEM Molecular Templates
$8.85 /

-0.1 (-1.12%)

MCRB Seres Therapeutics
$26.34 /

-1.2 (-4.36%)

KOD Kodiak Sciences
$130.37 /

-6.31 (-4.62%)

FOLD Amicus
$22.66 /

-0.28 (-1.22%)

ENTA Enanta
$41.12 /

+0.01 (+0.02%)

COGT Cogent Biosciences
$10.52 /

+0.56 (+5.62%)

BHC Bausch Health
$18.65 /

+0.065 (+0.35%)

ALXN Alexion
$122.16 /

+0.19 (+0.16%)

ALXN Alexion
$122.16 /

+0.19 (+0.16%)

STRO Sutro Biopharma
$16.76 /

-0.32 (-1.87%)

MCRB Seres Therapeutics
$26.34 /

-1.2 (-4.36%)

INCY Incyte
$85.42 /

+0.9 (+1.06%)

CMPS Compass Pathways
$44.73 /

-4.78 (-9.65%)

BHC Bausch Health
$18.65 /

+0.065 (+0.35%)

ALXN Alexion
$122.16 /

+0.19 (+0.16%)

Conference/Events
Evercore ISI to hold a virtual conference » 08:22
12/01/20
12/01
08:22
12/01/20
08:22
CMPS

Compass Pathways

$49.60 /

+2.26 (+4.77%)

, INSM

Insmed

$39.02 /

-0.8 (-2.01%)

, ALXN

Alexion

$121.96 /

-2.03 (-1.64%)

, ENTA

Enanta

$41.32 /

-1.5 (-3.50%)

, NKTX

Nkarta

$32.91 /

-1.23 (-3.60%)

, HRC

Hill-Rom

$94.86 /

-0.71 (-0.74%)

, DRNA

Dicerna

$25.32 /

+0.79 (+3.22%)

, ZBH

Zimmer Biomet

$149.21 /

-0.79 (-0.53%)

, INCY

Incyte

$84.52 /

+1.33 (+1.60%)

, MTEM

Molecular Templates

$8.93 /

-0.18 (-1.98%)

, KOD

Kodiak Sciences

$136.67 /

+1.14 (+0.84%)

, ICLR

Icon

$194.85 /

+4.45 (+2.34%)

, MCRB

Seres Therapeutics

$27.58 /

-1.39 (-4.80%)

, NVST

Envista

$29.75 /

+0.14 (+0.47%)

, EXEL

Exelixis

$19.16 /

-0.26 (-1.34%)

, FATE

Fate Therapeutics

$58.47 /

+0.54 (+0.93%)

, FOLD

Amicus

$22.94 /

-0.31 (-1.33%)

, COGT

Cogent Biosciences

$10.02 /

+0.23 (+2.35%)

, BHC

Bausch Health

$18.58 /

-0.97 (-4.96%)

, TBIO

Translate Bio

$22.24 /

+2.9 (+14.99%)

, STRO

Sutro Biopharma

$17.08 /

-0.02 (-0.12%)

, PRAX

Praxis Precision Medicines

$40.94 /

+0.54 (+1.34%)

3rd Annual HealthCONx…

3rd Annual HealthCONx Virtual Conference will be held on December 1-3.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$149.21 /

-0.79 (-0.53%)

TBIO Translate Bio
$22.24 /

+2.9 (+14.99%)

STRO Sutro Biopharma
$17.08 /

-0.02 (-0.12%)

PRAX Praxis Precision Medicines
$40.94 /

+0.54 (+1.34%)

NVST Envista
$29.75 /

+0.14 (+0.47%)

NKTX Nkarta
$32.91 /

-1.23 (-3.60%)

MTEM Molecular Templates
$8.93 /

-0.18 (-1.98%)

MCRB Seres Therapeutics
$27.58 /

-1.39 (-4.80%)

KOD Kodiak Sciences
$136.67 /

+1.14 (+0.84%)

INSM Insmed
$39.02 /

-0.8 (-2.01%)

INCY Incyte
$84.52 /

+1.33 (+1.60%)

ICLR Icon
$194.85 /

+4.45 (+2.34%)

HRC Hill-Rom
$94.86 /

-0.71 (-0.74%)

FOLD Amicus
$22.94 /

-0.31 (-1.33%)

FATE Fate Therapeutics
$58.47 /

+0.54 (+0.93%)

EXEL Exelixis
$19.16 /

-0.26 (-1.34%)

ENTA Enanta
$41.32 /

-1.5 (-3.50%)

DRNA Dicerna
$25.32 /

+0.79 (+3.22%)

COGT Cogent Biosciences
$10.02 /

+0.23 (+2.35%)

CMPS Compass Pathways
$49.60 /

+2.26 (+4.77%)

BHC Bausch Health
$18.58 /

-0.97 (-4.96%)

ALXN Alexion
$121.96 /

-2.03 (-1.64%)

CMPS Compass Pathways
$49.60 /

+2.26 (+4.77%)

10/14/20 H.C. Wainwright
Compass Pathways initiated with a Buy at H.C. Wainwright
10/13/20 Evercore ISI
Compass Pathways initiated with an Outperform at Evercore ISI
10/13/20 Canaccord
Compass Pathways initiated with a Buy at Canaccord
10/13/20 Berenberg
Compass Pathways initiated with a Buy at Berenberg
INSM Insmed
$39.02 /

-0.8 (-2.01%)

11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
10/12/20 Stifel
Insmed resumed with a Buy at Stifel
04/23/20 JMP Securities
JMP reiterates $50 target on Insmed on planned COVID-19 trial
ALXN Alexion
$121.96 /

-2.03 (-1.64%)

11/20/20
Fly Intel: Top five analyst initiations
11/20/20 Bernstein
Alexion initiated with a Market Perform at Bernstein
11/19/20 Bernstein
Alexion initiated with a Market Perform at Bernstein
11/05/20 Citi
Alexion price target raised to $157 from $145 at Citi
ENTA Enanta
$41.32 /

-1.5 (-3.50%)

11/24/20 RBC Capital
Enanta price target lowered to $45 from $52 at RBC Capital
11/24/20 Evercore ISI
Evercore cautious on Enanta into 2021, starts with Underperform
11/23/20 Evercore ISI
Enanta initiated with an Underperform at Evercore ISI
10/26/20 Roth Capital
Enanta price target raised to $107 from $104 at Roth Capital
NKTX Nkarta
$32.91 /

-1.23 (-3.60%)

10/06/20 Mizuho
Nkarta CFO departure should not impact shares, says Mizuho
08/04/20 Mizuho
Mizuho starts Nkarta with Buy rating, $34 price target
08/04/20 Evercore ISI
Nkarta initiated with an Outperform at Evercore ISI
08/04/20 Stifel
Nkarta initiated with a Buy at Stifel
HRC Hill-Rom
$94.86 /

-0.71 (-0.74%)

11/04/20
Fly Intel: Top five analyst downgrades
11/04/20
Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
11/04/20 Needham
Hill-Rom downgraded to Hold from Buy at Needham
10/01/20 KeyBanc
Hill-Rom price target lowered to $115 from $138 at KeyBanc
DRNA Dicerna
$25.32 /

+0.79 (+3.22%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 Truist
Dicerna price target raised to $33 from $28 at SunTrust
ZBH Zimmer Biomet
$149.21 /

-0.79 (-0.53%)

11/09/20 SVB Leerink
Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
11/09/20 Credit Suisse
Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
11/09/20 Baird
Zimmer Biomet valuation discount to peers hard to justify, says at Baird
11/09/20 Oppenheimer
Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
INCY Incyte
$84.52 /

+1.33 (+1.60%)

11/06/20 RBC Capital
Incyte price target lowered to $86 from $96 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
MTEM Molecular Templates
$8.93 /

-0.18 (-1.98%)

09/08/20 Jefferies
Molecular Templates initiated with a Buy at Jefferies
08/07/20
Molecular Templates files $300M mixed securities shelf
05/12/20 Oppenheimer
Molecular Templates price target raised to $22 from $16 at Oppenheimer
03/25/20
Fly Intel: Top five analyst initiations
KOD Kodiak Sciences
$136.67 /

+1.14 (+0.84%)

11/30/20
Fly Intel: Top five analyst downgrades
11/30/20 JPMorgan
Kodiak Sciences downgraded to Neutral on valuation at JPMorgan
11/30/20 JPMorgan
Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan
11/16/20 Morgan Stanley
Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts
ICLR Icon
$194.85 /

+4.45 (+2.34%)

10/23/20 Deutsche Bank
Icon price target raised to $179 from $170 at Deutsche Bank
10/23/20 Mizuho
Icon price target raised to $217 from $195 at Mizuho
10/22/20 Credit Suisse
Icon price target raised to $235 from $230 at Credit Suisse
07/27/20 Truist
SunTrust raises price targets on select late-stage CROs
MCRB Seres Therapeutics
$27.58 /

-1.39 (-4.80%)

11/09/20 Oppenheimer
Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
11/09/20 Piper Sandler
Seres Therapeutics price target raised to $49 from $40 at Piper Sandler
10/27/20 Oppenheimer
Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
10/26/20 Oppenheimer
Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
NVST Envista
$29.75 /

+0.14 (+0.47%)

10/30/20 JPMorgan
Envista price target raised to $30 from $28 at JPMorgan
10/30/20 Piper Sandler
Envista price target raised to $28 from $22 at Piper Sandler
07/31/20 Piper Sandler
Envista price target raised to $22 from $20 at Piper Sandler
06/16/20
Fly Intel: Top five analyst initiations
EXEL Exelixis
$19.16 /

-0.26 (-1.34%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
FATE Fate Therapeutics
$58.47 /

+0.54 (+0.93%)

11/24/20 Truist
Fate Therapeutics price target raised to $65 from $40 at Truist
11/09/20 Citi
Fate Therapeutics price target raised to $63 from $40 at Citi
11/08/20 Oppenheimer
Fate Therapeutics price target raised to $60 from $40 at Oppenheimer
11/06/20 Piper Sandler
Fate Therapeutics price target raised to $71 from $59 at Piper Sandler
FOLD Amicus
$22.94 /

-0.31 (-1.33%)

11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Amicus initiated with a Hold at Berenberg
11/06/20 Baird
Amicus price target raised to $25 from $20 at Baird
08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
COGT Cogent Biosciences
$10.02 /

+0.23 (+2.35%)

11/10/20 Wedbush
Cogent Biosciences price target raised to $24 from $6 at Wedbush
10/14/20 Ladenburg
Ladenburg starts Cogent Biosciences with Buy, $4 price target
10/14/20 Ladenburg
Cogent Biosciences initiated with a Buy at Ladenburg
BHC Bausch Health
$18.58 /

-0.97 (-4.96%)

11/05/20 Piper Sandler
Bausch Health price target lowered to $25 from $26 at Piper Sandler
10/26/20 Barclays
Bausch Health price target raised to $29 from $28 at Barclays
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 BofA
Bausch Health upgraded to Neutral from Underperform at BofA
TBIO Translate Bio
$22.24 /

+2.9 (+14.99%)

10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
07/07/20 H.C. Wainwright
Translate Bio price target raised to $32 from $18 at H.C. Wainwright
07/06/20
Fly Intel: Top five analyst initiations
07/06/20 William Blair
Translate Bio initiated with an Outperform at William Blair
STRO Sutro Biopharma
$17.08 /

-0.02 (-0.12%)

11/06/20 Piper Sandler
Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
PRAX Praxis Precision Medicines
$40.94 /

+0.54 (+1.34%)

11/17/20 Piper Sandler
Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
11/11/20
Fly Intel: Top five analyst initiations
11/11/20 Wedbush
Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
11/11/20 Wedbush
Praxis Precision Medicines initiated with an Outperform at Wedbush
ZBH Zimmer Biomet
$149.21 /

-0.79 (-0.53%)

STRO Sutro Biopharma
$17.08 /

-0.02 (-0.12%)

NVST Envista
$29.75 /

+0.14 (+0.47%)

MTEM Molecular Templates
$8.93 /

-0.18 (-1.98%)

MCRB Seres Therapeutics
$27.58 /

-1.39 (-4.80%)

KOD Kodiak Sciences
$136.67 /

+1.14 (+0.84%)

INSM Insmed
$39.02 /

-0.8 (-2.01%)

INCY Incyte
$84.52 /

+1.33 (+1.60%)

ICLR Icon
$194.85 /

+4.45 (+2.34%)

HRC Hill-Rom
$94.86 /

-0.71 (-0.74%)

FOLD Amicus
$22.94 /

-0.31 (-1.33%)

FATE Fate Therapeutics
$58.47 /

+0.54 (+0.93%)

EXEL Exelixis
$19.16 /

-0.26 (-1.34%)

ENTA Enanta
$41.32 /

-1.5 (-3.50%)

DRNA Dicerna
$25.32 /

+0.79 (+3.22%)

COGT Cogent Biosciences
$10.02 /

+0.23 (+2.35%)

CMPS Compass Pathways
$49.60 /

+2.26 (+4.77%)

BHC Bausch Health
$18.58 /

-0.97 (-4.96%)

ALXN Alexion
$121.96 /

-2.03 (-1.64%)

  • 02
    Dec
  • 18
    Nov
  • 16
    Oct
  • 18
    Sep
  • 13
    Aug
  • 10
    Jul
  • 26
    Jun
  • 09
    Jun
  • 12
    May
  • 05
    May
  • 04
    Dec
TBIO Translate Bio
$22.24 /

+2.9 (+14.99%)

FOLD Amicus
$22.94 /

-0.31 (-1.33%)

CMPS Compass Pathways
$49.60 /

+2.26 (+4.77%)

ALXN Alexion
$121.96 /

-2.03 (-1.64%)

TBIO Translate Bio
$22.24 /

+2.9 (+14.99%)

STRO Sutro Biopharma
$17.08 /

-0.02 (-0.12%)

PRAX Praxis Precision Medicines
$40.94 /

+0.54 (+1.34%)

NVST Envista
$29.75 /

+0.14 (+0.47%)

NKTX Nkarta
$32.91 /

-1.23 (-3.60%)

MTEM Molecular Templates
$8.93 /

-0.18 (-1.98%)

MCRB Seres Therapeutics
$27.58 /

-1.39 (-4.80%)

KOD Kodiak Sciences
$136.67 /

+1.14 (+0.84%)

FOLD Amicus
$22.94 /

-0.31 (-1.33%)

ENTA Enanta
$41.32 /

-1.5 (-3.50%)

COGT Cogent Biosciences
$10.02 /

+0.23 (+2.35%)

BHC Bausch Health
$18.58 /

-0.97 (-4.96%)

ALXN Alexion
$121.96 /

-2.03 (-1.64%)

ALXN Alexion
$121.96 /

-2.03 (-1.64%)

STRO Sutro Biopharma
$17.08 /

-0.02 (-0.12%)

MCRB Seres Therapeutics
$27.58 /

-1.39 (-4.80%)

INCY Incyte
$84.52 /

+1.33 (+1.60%)

CMPS Compass Pathways
$49.60 /

+2.26 (+4.77%)

BHC Bausch Health
$18.58 /

-0.97 (-4.96%)

ALXN Alexion
$121.96 /

-2.03 (-1.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.